TGFB1 and neoplasm: The inhibition of TGF‐β and vascular endothelial growth factor (VEGF) signaling pathways synergistically reduces Tregs, increases infiltrating T cells, and restores tumor sensitivity to anti‐PD‐1 and anti‐CTLA‐4 treatments, eradicating immunogenic tumors [140].